Učestalost smanjenja PCT (plateletkrit ili trombokrit)  kod COVID-19 pozitivnih pacijenata - dijagnostički i epidemiološki značaj

Dalibor Jevtić; Slavoljub   Janković; Danijela Marković; Milena Jevtić; Milan Đorđević; Aleksa Janković

doi:10.5937/opmed0-47424

Dalibor D. Jevtić Dom zdravlja „Dr Ljubinko Đorđević“ Svrljig, Srbija
Slavoljub D. Janković Dom zdravlja Niš
Danijela Z. Marković Dom zdravlja "Dr Ljubinko Đorđević" Svrljig
Milena D. Jevtić Dom zdravlja "Dr Ljubinko Đorđević" Svrljig
Milan V. Đorđević Urgentni centar UKC Niš,
Aleksa S. Janković Vojska Srbije

DOI: https://doi.org/10.5937/opmed0-47424

Ključne reči: trombocit, infekcija, D-dimer, virus

Sažetak

Uvod: Trombociti imaju važnu ulogu u patogenezi COVID-19, te im parametri variraju u različitim fazama bolesti.Značaj plateletkrita u COVID-19 je nedovoljno poznat.
Cilj: Ispitati dijagnostički značaj trombokrita u COVID-19.
Metode: U periodu od januara do marta i od septembra do decembra 2021. godine, analizirano je 440 pacijenata kojisu se prvi put javili na pregled u COVID ambulantu Doma zdravlja Niš zbog sumnje na COVID-19, gde im je nakon pregleda urađena analiza krvne slike. Testom je potvrđena infekcija COVID-19. Analiziran je plateletkrit iz analize krvi pri prvom pregledu. Kontrolnu grupu su činili pacijenti iz “zelene zone”, i to 60 bolesnika u periodu januar–decembar 2021. godine, i još 48 pacijenata iz perioda pre COVID-19, pre 2020. godine.
Rezultati: U prvom periodu snižen plateletkrit je imalo 48,4% žena i 63,3% muškaraca, a ukupno od 111 pacijenata, snižen plateletkrita je imalo 54,9%. U drugom periodu snižen plateletkrit je imalo 72,2% žena i 85% muškaraca, a ukupno od 329 pacijenata snižen plateletkrit je imalo 78,7%.
Zaključak: Trombokrit je smanjen kod značajnog broja pacijenata koji se prvi put javljaju zbog simptoma COVID-19, te bi na osnovu samo analize plateletkrita sa velikom verovatnoćom moglo da posumnja da se radi o infekciji COVID-19.

Reference

Khismatullin RR, Ponomareva AA, Nagaswami C, Ivaeva RA, Montone KT, Weisel JW, et al. Pathology of lung-specific thrombosis and inflammation in COVID-19. J Thromb Haemost 2021; 19(12): 3062–72

Flaumenhaft R, Enjyoji K, Schmaier AA. Vasculopathy in COVID-19. Blood 2022; 140(3): 222–35.

Barçın C. Thrombosis in COVID-19: We still need to learn a lot. Anatol J Cardiol 2021; 25(9): 600.

Andrade BS, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Freitas ADS, et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses 2021; 13(4): 700.

Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020; 26: 1076029620938149.

Katneni UK, Alexaki A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, et al. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thromb Haemost 2020; 120(12): 1668–79.

Al-Samkari H, Leaf RSK, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID 19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136(4): 489–500.

Castro RA, Frishman WH. Thrombotic Complications of COVID-19 Infection: A Review. Cardiol Rev 2021; 29(1): 43–7.

Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18(7): 1738–42. doi:10.1111/jth.14850. Epub 2020 Jun 24.PMID: 32302438

Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, et al. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev 2021; 46: 100745. doi:10.1016/j.blre.2020.100745. Epub 2020 Aug 24.

Khandelwal G, Ray A, Sethi S, Harikrishnan HK, Khandelwal C, Sadasivam B. COVID-19 and thrombotic complications-the role of anticoagulants, antiplatelets and thrombolytics. J Family Med Prim Care 2021; 10(10): 3561–7. doi:10.4103/jfmpc.jfmpc_1297_20. Epub 2021 Nov 5.

Bežovan D. Uzroci trombocitopenije u Covid-19 bolesnika. Diplomski rad. Sveučilište u Zagrebu, Medicinski fakultet, 2021. Dostupno na: https://repozitorij.mef.unizg.hr/islandora/object/mef:3966

Pranata R, Lim MA, Yonas E, Huang I, Nasution SA, Setiati S, et al. Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis. Epidemiol Infect 2021; 149: e40.

Mansoori et al., “Association between Biochemical and Hematologic Factors with COVID-19 Using Data Mining Methods.” BMC Infect Dis. 2023 Dec 21;23(1):897.doi: 10.1186/s12879-023-08676-0.

Gadó K, Kovács AK, Domján G, Nagy ZZ, Bednárik GD. COVID-19 and the elderly. Physiol Int. Published online May 16, 2022. doi:10.1556/2060.2022.00203

Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 2021;21(1):321. doi:10.1186/s12877-021-02261-3